Pricing Log in Create free account
Friday 6 November 2026 Export BMRN’s income statement to Excel — free account

BioMarin Pharmaceutical Inc.

BMRN Healthcare Biotechnology

BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024.

Revenue
+32.0%
EPS
−296.6%
Free cash flow
−52.3%
Total debt
+599.5%

Quarter to September 2026, against a year earlier

55.56 0.56 −1.00%
Market cap
$10.9B
P/E
0.0×
Fwd P/E
32.7×
Dividend yield
—
F-score
5/9
Altman Z
5.67
Beneish M
−2.49
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

BioMarin Pharmaceutical Inc. (BMRN) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 14 added · 10 removed · 23 modified
P2I1A: no comparison — low extraction confidence
8-K Nov 2, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 6, 2026 2.02 Results of operations and financial condition
8-K Sep 24, 2026 1.01 Entry into a material definitive agreement
8-K Sep 15, 2026 8.01 Other events
8-K Sep 10, 2026 5.02 Departure or appointment of directors or officers Officer departure
8-K Aug 31, 2026 8.01 Other events
8-K Aug 30, 2026 1.01 Entry into a material definitive agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Aug 17, 2026 1.01 Entry into a material definitive agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 23 added · 11 removed · 32 modified
P2I1A: no comparison — low extraction confidence
8-K Aug 6, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K/A Apr 27, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jun 2, 2026 5.02 Departure or appointment of directors or officers; 5.07 Submission of matters to a vote of security holders
10-Q Mar 31, 2026
8-K May 4, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 27, 2026 1.01 Entry into a material definitive agreement; 2.01 Completion of an acquisition or disposition; 2.03 Creation of a direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Apr 23, 2026 8.01 Other events
8-K Mar 16, 2026 8.01 Other events
10-K Dec 31, 2025 1: 20 added · 17 removed · 71 modified
1A: 51 added · 4 removed · 102 modified
7: 20 added · 10 removed · 27 modified
8-K Feb 23, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 12, 2026 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Jan 29, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Jan 26, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jan 12, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Dec 19, 2025 8.01 Other events
8-K Dec 19, 2025 1.01 Entry into a material definitive agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Dec 11, 2025 5.02 Departure or appointment of directors or officers
10-Q Sep 30, 2025
8-K Oct 27, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 7, 2025 2.02 Results of operations and financial condition
10-Q Jun 30, 2025
8-K Aug 4, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K May 1, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024
8-K Feb 19, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Oct 29, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Aug 5, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 24, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 22, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.